title: Long-term benzodiazepine users 3 years after participation in a discontinuation program.
abstract: OBJECTIVE
  Clinical status and use of benzodiazepines and other psychotropic drugs at follow-up were assessed in patients who had been chronically dependent on benzodiazepines and had been referred for participation in a discontinuation study.
  
  
  METHODS
  Of 123 benzodiazepine-dependent patients screened for entry into a tapered discontinuation program, 48 had completed the program, 38 had not, and 37 had not undergone drug tapering. Follow-up information was obtained through a structured telephone interview and a mail questionnaire that included a global severity scale assessing anxiety and depression and the Hopkins Symptom Checklist. The time to follow-up was 2.7-5.0 years, and the mean +/- SD interval between screening and follow-up was 2.9 +/- 0.9 years.
  
  
  RESULTS
  Outcome at follow-up significantly favored the patients who had completed the discontinuation program; 73% were not using benzodiazepines, compared to 39% in the unsuccessful taper group and 14% in the no-taper group. Moderate or marked anxiety was still reported by 35% of the patients who were taking benzodiazepines and 25% of those who were not. At follow-up, 22% of the patients were being treated with nonbenzodiazepine psychotropic agents, primarily antidepressants.
  
  
  CONCLUSIONS
  The high percentage of patients who were benzodiazepine-free at follow-up and the continued anxiety and depression present in many patients suggest that some patients may have been taking benzodiazepines because of chronic or recurrent anxiety or depression, not physical dependence.
authors.affiliation: Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia.
authors.forename: K
authors.initials: K
authors.lastname: Rickels
authors.forename: W G
authors.initials: WG
authors.lastname: Case
authors.forename: E
authors.initials: E
authors.lastname: Schweizer
authors.forename: F
authors.initials: F
authors.lastname: Garcia-Espana
authors.forename: R
authors.initials: R
authors.lastname: Fridman
mesh_terms: D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002908:Chronic Disease; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D003937:Diagnosis, Differential; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010043:Outcome and Process Assessment, Health Care / Q000706:statistics & numerical data; D011569:Psychiatric Status Rating Scales; D012008:Recurrence; D012044:Regression Analysis; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*
chemical_list: D001569:Benzodiazepines